Literature DB >> 16491428

Lack of tolerance to the suppressing effect of rimonabant on chocolate intake in rats.

Gian Luigi Gessa1, Alessandro Orrù, Paola Lai, Paola Maccioni, Rossella Lecca, Carla Lobina, Mauro A M Carai, Giancarlo Colombo.   

Abstract

RATIONALE AND
OBJECTIVES: Previous work indicated that tolerance to the anorectic effect of the cannabinoid CB1 receptor antagonist/inverse agonist, rimonabant, developed rather rapidly in rats and mice given access to a standard rodent chow. The present study was designed to investigate whether the reducing effect of rimonabant on intake of a highly palatable food such as a chocolate-flavoured beverage underwent a development of tolerance as rapid as that manifested on intake of a standard rodent chow.
MATERIALS AND METHODS: To this aim, Wistar rats were concurrently exposed, with unlimited access for 24 h/day, to the chocolate-flavoured beverage, regular food pellets and water. Rimonabant (0, 1.25, 2.5 and 5 mg/kg; i.p.) was administered once a day for 21 consecutive days.
RESULTS: Rimonabant administration resulted in a dose-dependent suppression of the high, daily intake of the chocolate-flavoured beverage; this effect lasted for the entire 21-day treatment period, without any apparent development of tolerance. Conversely, rimonabant-induced reduction in daily intake of regular food pellets was of a smaller magnitude and was limited to the first 3-4 days of treatment.
CONCLUSIONS: Together, these results indicate that chronically administered rimonabant was more effective and longer-lasting in reducing the intake of a highly palatable food than that of regular food pellets in rats. These results also suggest that rimonabant may be more active on the hedonic rather than nutritive properties of diets.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16491428     DOI: 10.1007/s00213-006-0327-1

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  29 in total

1.  SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset.

Authors:  J Simiand; M Keane; P E Keane; P Soubrié
Journal:  Behav Pharmacol       Date:  1998-03       Impact factor: 2.293

2.  Functional interaction between opioid and cannabinoid receptors in drug self-administration.

Authors:  M Navarro; M R Carrera; W Fratta; O Valverde; G Cossu; L Fattore; J A Chowen; R Gomez; I del Arco; M A Villanua; R Maldonado; G F Koob; F Rodriguez de Fonseca
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

Review 3.  Rimonabant: the first therapeutically relevant cannabinoid antagonist.

Authors:  Mauro A M Carai; Giancarlo Colombo; Gian Luigi Gessa
Journal:  Life Sci       Date:  2005-09-23       Impact factor: 5.037

4.  Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats.

Authors:  F Chaperon; P Soubrié; A J Puech; M H Thiébot
Journal:  Psychopharmacology (Berl)       Date:  1998-02       Impact factor: 4.530

5.  Marijuana intoxication common experiences.

Authors:  C T Tart
Journal:  Nature       Date:  1970-05-23       Impact factor: 49.962

6.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors:  Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

Review 7.  Endocannabinoid system and alcohol addiction: pharmacological studies.

Authors:  Giancarlo Colombo; Salvatore Serra; Giovanni Vacca; Mauro A M Carai; Gian Luigi Gessa
Journal:  Pharmacol Biochem Behav       Date:  2005-06       Impact factor: 3.533

8.  Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats.

Authors:  Benoît Forget; Michel Hamon; Marie-Hélène Thiébot
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

9.  The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.

Authors:  M Bensaid; M Gary-Bobo; A Esclangon; J P Maffrand; G Le Fur; F Oury-Donat; P Soubrié
Journal:  Mol Pharmacol       Date:  2003-04       Impact factor: 4.436

10.  Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats.

Authors:  S P Vickers; L J Webster; A Wyatt; C T Dourish; G A Kennett
Journal:  Psychopharmacology (Berl)       Date:  2003-03-11       Impact factor: 4.530

View more
  15 in total

Review 1.  The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence.

Authors:  Giancarlo Colombo; Alessandro Orrù; Paola Lai; Claudia Cabras; Paola Maccioni; Marina Rubio; Gian Luigi Gessa; Mauro A M Carai
Journal:  Mol Neurobiol       Date:  2007-07-03       Impact factor: 5.590

2.  The neutral cannabinoid CB₁ receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat.

Authors:  Nina L Cluny; Adam P Chambers; V Kiran Vemuri; Jodianne T Wood; Lindsay K Eller; Carmelina Freni; Raylene A Reimer; Alexandros Makriyannis; Keith A Sharkey
Journal:  Pharmacol Biochem Behav       Date:  2010-11-04       Impact factor: 3.533

3.  Rimonabant's reductive effects on high densities of food reinforcement, but not palatability, in lean and obese Zucker rats.

Authors:  Jessica L Buckley; Erin B Rasmussen
Journal:  Psychopharmacology (Berl)       Date:  2014-01-08       Impact factor: 4.530

Review 4.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

5.  Rimonabant precipitates anxiety in rats withdrawn from palatable food: role of the central amygdala.

Authors:  Angelo Blasio; Attilio Iemolo; Valentina Sabino; Stefania Petrosino; Luca Steardo; Kenner C Rice; Pierangelo Orlando; Fabio Arturo Iannotti; Vincenzo Di Marzo; Eric P Zorrilla; Pietro Cottone
Journal:  Neuropsychopharmacology       Date:  2013-06-24       Impact factor: 7.853

Review 6.  Clinical review: Regulation of food intake, energy balance, and body fat mass: implications for the pathogenesis and treatment of obesity.

Authors:  Stephan J Guyenet; Michael W Schwartz
Journal:  J Clin Endocrinol Metab       Date:  2012-01-11       Impact factor: 5.958

Review 7.  Cannabinoids in eating disorders and obesity.

Authors:  Francisco Arias Horcajadas
Journal:  Mol Neurobiol       Date:  2007-07-07       Impact factor: 5.590

8.  Cannabinoid-1 receptor antagonists reduce caloric intake by decreasing palatable diet selection in a novel dessert protocol in female rats.

Authors:  Clare M Mathes; Marco Ferrara; Neil E Rowland
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-04-30       Impact factor: 3.619

9.  Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users.

Authors:  Marilyn A Huestis; Susan J Boyd; Stephen J Heishman; Kenzie L Preston; Denis Bonnet; Gerard Le Fur; David A Gorelick
Journal:  Psychopharmacology (Berl)       Date:  2007-07-10       Impact factor: 4.530

10.  Effects of the cannabinoid antagonist SR141716 (rimonabant) and d-amphetamine on palatable food and food pellet intake in non-human primates.

Authors:  Richard W Foltin; Margaret Haney
Journal:  Pharmacol Biochem Behav       Date:  2007-03-15       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.